28 – 29 June 2021
Lausanne (exact location will be announced soon)
Goals of the module
- have an overview on sex differences in oncology and the scientific, clinical and societal implications of sex differences for prevenetion, diagnosis and treatment of cancer.
- are familiar with the combined impact of sexual hormones and sex chromosomes on cancer susceptibility with a focus on intrinsic control of cancer initiating cell populations, tumor microenvironment and systemic determinants of cancer development.
Content of the module
- Rationale for considering gender in cancer prevention and treatment
- Sex differences in epidemiology of various cancers
- Sex and gender differences in carcinogen exposition (UV light, smoking, environmental carcinogens)
- Sex chromosomes and their impact on cancer susceptibility
- Estrogens and their impact on cancer risk in females and males
- Endocrine disruptors
- Androgens and their impact on cancer risk in females and males
- Impact of sex on systemic determinants of cancer development
- tumor microenvironment
- cancer initiating cells
- Clinical implications of sex and gender differences in cancer
- Sex differences in response and toxicity of anticancer therapies (cytotoxics, targeted therapies and immunotherapies)
- Sex differences in oncological surgery and radiotherapy outcomes
- Implications for clinical trial design and reporting of results
- Sex-specific drug dosing strategies?
- Sex-specific cancer prevention efforts?
Prof. Dr. Paolo Dotto, Department of Biochemistry, University of Lausanne/ International Cancer Prevention Institute (Chair)
Dr. med. Berna Özdemir, Department of Oncology, Lausanne University Hospital and University of Lausanne/ International Cancer Prevention Institute
PD Dr. med. Anna Wagner, Department of Oncology, Lausanne University Hospital and University of Lausanne
Registration form and Deadline
Deadline 20 May 2021, Registration form